Encouraging results from the Phase 1a clinical trial.
http://neurodyn-inc....eimers-disease/
Memogain (Gln-1062) is an inactive pro-drug of galantamine, the latter being a plant alkaloid approved for the treatment of mild to moderate Alzheimer's disease. Memogain has more than 15-fold higher bioavailability in the brain than the same doses of galantamine.
http://www.ncbi.nlm....ubmed/19669943/
Edited by Metagene, 26 October 2014 - 06:35 PM.